The UK government announced Thursday in its official response to the Health Select Committee’s report on the future role of the National Institute for Health and Clinical Excellence, that the agency will take responsibility for determining the full value of all drugs when a new pricing system is implemented in 2014. The move broadens the scope of NICE by allowing it to gauge the benefits and costs of individual drugs. The agency will collaborate with the Department of Health and other stakeholders to establish how it will perform its new role.
The value-based pricing system, first announced in 2010, will be used to assess the value of new medicines.
In January, the House of Commons Health Committee called on the UK government to provide further detail on its plans, noting that a lack of clarity was creating uncertainty for the industry and physicians.
To read more Top Story articles, click here.